Skip to content
AncillaryWADA Status UnclearCompare

Kisspeptin

Also known as: Kisspeptin-10, KP-10, Kisspeptin-54, KP-54, Metastin, KISS1 peptide

2
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

Kisspeptin is a research peptide that acts as the master upstream regulator of the HPG axis. Per Dhillo et al. (JCEM 2005), a 90-minute IV infusion of kisspeptin-54 (4 pmol/kg·min) raised mean LH to 10.8 U/L vs 4.2 U/L on saline (~2.6-fold), with only a modest rise in testosterone (24.9 vs 21.7 nmol/L, ~15%) and FSH, in healthy men. Effects are acute and transient due to a very short half-life (KP-10 ~4 min, KP-54 ~27.6 min), and it is not FDA-approved, research status only. Used theoretically for PCT/axis support, not muscle-building enhancement; like gonadorelin, it restores/stimulates the body's own upstream signaling rather than supplying anabolic hormone. Rated 2, matching other pure axis-support/ancillary compounds (e.g. gonadorelin) that do not move the needle on muscular potential.

Overview

A hypothalamic neuropeptide that acts as the master upstream regulator of the HPG axis by stimulating GnRH release. Binds to KISS1R (GPR54) on GnRH neurons, triggering pulsatile GnRH secretion. Available as Kisspeptin-10 (shorter half-life) and Kisspeptin-54 (longer half-life). Acutely increases LH roughly 2- to 3-fold, with more modest FSH and testosterone rises, in men. Theoretically attractive for PCT due to upstream mechanism, but short half-life and research status limit practical application.

Important Warnings

  • •Research compound only - not FDA-approved for any indication
  • •Very short half-life (especially KP-10: ~4 min) requires frequent dosing
  • •Injectable only - no oral bioavailability
  • •Limited human data for post-AAS recovery specifically
  • •Continuous administration can cause desensitization (tachyphylaxis)
  • •May be prohibited in competitive sports (check current WADA guidelines)
  • •Requires intact GnRH neurons and pituitary - will not work if these are damaged
  • •Opioids and severe caloric restriction suppress kisspeptin response
  • •Not readily available - gray market/research supplier only

Purpose & Use Cases

HPG Axis Stimulation

Acts upstream of GnRH for more physiological axis stimulation. A 90-min kisspeptin-54 IV infusion (4 pmol/kg·min) raised mean LH to 10.8 U/L vs 4.2 U/L on saline (~2.6-fold), with a modest testosterone rise (24.9 vs 21.7 nmol/L) and FSH increase, in healthy men (Dhillo et al., JCEM 2005).

Theoretical PCT Application

May allow more natural axis restoration by stimulating endogenous GnRH pulse generator rather than imposing artificial stimulation. Limited data in post-AAS recovery.

Fertility Research

Studied for hypothalamic amenorrhea (restored LH pulsatility in 2-week studies), IVF triggers (reduced OHSS risk vs hCG), and hypogonadotropic hypogonadism diagnosis.

Diagnostic Tool

Used in research to assess HPG axis function. Blunted response indicates hypothalamic dysfunction; normal response suggests intact kisspeptin-GnRH-pituitary pathway.

Benefits

  • Acts upstream of GnRH - more "physiological" HPG axis stimulation
  • Acutely increases LH (~2-3x) in healthy men
  • Well-tolerated in clinical studies
  • Does not directly suppress endogenous production (unlike exogenous hormones)
  • Integrates with metabolic/stress signals naturally
  • Lower OHSS risk than hCG in IVF applications
  • Short half-life prevents accumulation-related toxicity
  • Not a controlled substance

Good to Know

The furthest-upstream lever on the whole axis

Kisspeptin sits ABOVE GnRH: kisspeptin neurons are the gatekeepers that tell the GnRH neurons to fire. So it is the most "physiological" way to stimulate the HPG axis. It drives your own pulsatile GnRH, which drives LH/FSH, which drives testosterone, rather than imposing a hormone from outside. In the restart hierarchy it is one step above gonadorelin (GnRH), which is above HMG (LH+FSH) and HCG (LH).

Great biology, impractical drug

A single dose raises LH several-fold and testosterone modestly in men, but the half-life is minutes (KP-10 ~4 min, KP-54 ~28 min) and it is injectable and research-only. Effects are acute and transient, sustained use needs pulsatile dosing, and there is very little real data in post-AAS recovery specifically. Attractive in theory, rarely practical.

It needs an intact axis to work

Because it acts at the very top, kisspeptin only helps if the GnRH neurons and pituitary are functional. It will not rescue a damaged pituitary. Opioids and severe caloric restriction blunt the kisspeptin response, which is part of why under-eating and opioid use suppress testosterone.

Continuous exposure desensitizes it too

Like GnRH itself, steady non-pulsatile administration can cause tachyphylaxis (the response fades). Pulsatile dosing (roughly every 90 minutes in studies) maintains responsiveness far better than continuous exposure.

Dosage Guidelines

Experience LevelDosage Range
Beginner100 – 300 mcg/day
Intermediate1400 – 4200 mcg/day
Advanced4200 – 5600 mcg/day
Frequency
Not a chronic daily protocol - dosed as a single IV/SC bolus per administration in research. Sustained axis stimulation requires pulsatile SC dosing roughly every 90 minutes (continuous non-pulsatile exposure causes tachyphylaxis).
Typical Cycle Length
1 – 2 weeks
Notes

There is no established recreational/self-administration protocol - these figures are clinical research doses converted from nmol/kg to a mass equivalent for a ~75kg adult using kisspeptin-54's MW (5857.4 Da; Cayman Chemical/SBS Genetech CoA data), since KP-54's longer half-life (~28 min vs KP-10's ~4 min) makes it the more practical of the two forms. Low end (~0.24-0.72 nmol/kg, ~100-300mcg) is illustrative of low-dose axis-stimulation infusion/dose-finding studies; the mid/high end (3.2-12.8 nmol/kg, ~1,400-5,600mcg) reflects the actual SC bolus dose-response arms tested as an IVF oocyte-maturation trigger in Abbara et al. (JCEM 2015) - the paper's four tested doses were 3.2, 6.4, 9.6 and 12.8 nmol/kg, not a continuous range down to fractional nmol/kg. A KP-10 bolus (MW 1302.5 Da) would need roughly 4.5x less mass than KP-54 for the same nmol/kg dose. "/day" cadence is used here only for the calculator's per-administration input - it is not dosed daily in practice.

Side Effects

Flushing

common
Severity
1/5

20-40% incidence. Transient warmth/redness, resolves within minutes.

Mitigation

Self-limiting. No intervention needed.

Injection Site Reactions

common
Severity
1/5

Redness, swelling at subcutaneous injection site.

Mitigation

Rotate injection sites.

Fatigue

uncommon
Severity
1/5

Occasional transient fatigue reported in studies.

Mitigation

Usually resolves quickly.

Nausea

uncommon
Severity
1.5/5

Occasional, dose-dependent.

Mitigation

Reduce dose if persistent.

Headache

uncommon
Severity
1/5

Usually transient.

Mitigation

Self-limiting.

General Mitigation Strategies

Generally very well-tolerated in clinical trials. No serious adverse events attributed to kisspeptin in published studies. Short half-life limits accumulation-related toxicity. No significant effects on blood pressure, heart rate, glucose, lipids, or liver enzymes observed. Flushing is most common side effect but transient.

Post Cycle Therapy (PCT)

✓PCT Not Required

Kisspeptin IS a potential PCT compound itself - it stimulates the HPG axis. Does not suppress endogenous function. Research status limits practical PCT application. Theoretically superior to GnRH for axis restart as it acts upstream.

How It Works

Kisspeptin binds to KISS1R (GPR54) on GnRH neurons in the hypothalamus, coupling to Gq/11 proteins and activating phospholipase C. This produces IP3 and DAG, triggering intracellular calcium release that stimulates pulsatile GnRH secretion. Acts one step upstream of GnRH - kisspeptin neurons are the "gatekeepers" of the HPG axis, integrating metabolic signals from leptin, insulin, and nutritional status.

Fundamentals

Reference on the practices relevant to Kisspeptin: how they are done and where they go wrong. Not a recommendation to use it.

Sterile technique & injection-site infection→

Avoiding abscesses and cellulitis

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

Common Stacks

  • Kisspeptin (research) + HCG - theoretical combination for comprehensive axis/testicular stimulation
  • Kisspeptin + SERM - both increase gonadotropins through different mechanisms
  • Kisspeptin-54 preferred over KP-10 due to longer half-life
  • Pulsatile dosing (every 90 min) better than continuous for sustained effect
  • Not practical for most users due to research status and dosing complexity

WADA Status

❓WADA Status Unclear
Category: S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics
In-Competition: ProhibitedOut-of-Competition: Prohibited

Kisspeptin stimulates GnRH/gonadotrophin release, the same mechanism class as gonadorelin, which is explicitly prohibited under S2.2 ("gonadotrophins... and their releasing factors"). Whether kisspeptin itself is explicitly named on the current list could not be independently confirmed here - treat it as very likely captured by the S2.2 releasing-factor / "similar biological effect" language and verify the current-year list before competition.

References

Last updated: July 18, 2026